Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus fluorouracil and cisplatin as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma
ChiCTR2000039571Phase 4Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Nov 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, fluorouracil and cisplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: 6-month progression-free survival rate. Started Nov 2020; status: recruiting.
02
Drugs
camrelizumabfluorouracilcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2000039571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039571.